PTC Therapeutics (NASDAQ:PTCT) has received FDA approval for its gene replacement therapy Kebilidi for the treatment of ...

The FDA has followed in the footsteps of its European counterparts and granted accelerated approval to PTC Therapeutics’ gene ...

At the start of the year, the company said it expected to make as much as $1 billion in revenue ... 2024 Future of ...

Future of Healthcategory Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free November 13, 2024 ...

To honor the fifth anniversary of Death Stranding, creator Hideo Kojima reveals the surprising origin behind the game's ...

Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $43 from $31 and keeps an Equal Weight rating on the shares. The ...

In a report released on November 8, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a ...